ARTS - AVODART After Radical Therapy For Prostate Cancer Study
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
ARI109924 will be a 2-year, multicentre, randomised, double-blind, placebo-controlled trial
assessing the efficacy and safety of dutasteride in extending time to prostate specific
antigen (PSA) doubling in men who have been treated for clinically localised prostate cancer
(PCa) with a radical therapy (radical prostatectomy, primary radiotherapy or salvage
radiotherapy) with curative intent but who experience a biochemical failure (PSA rise)
afterwards without signs or symptoms of metastases.